Current HCV Treatment by Genotype Ira M. Jacobson, MD
|
|
- Karin Freeman
- 5 years ago
- Views:
Transcription
1
2 Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine
3 Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle and how specific drugs target the HCV polypeptide sequence Explain circumstances where it is important to test for possible drug resistance Understand the landscape in regards to advances made in the evolution of treating HCV over the past 20+ years Understand the HCV genotypes and the drug regimens that work to eradicate HCV on each genotype
4 Distribution of Hepatitis C Genotypes Epidemiology of Infectious Diseases. Available at: Copyright John Hopkins Bloomberg School of Public Health. Creative Commons BY-NC-SA.
5 The HCV Life Cycle
6 T. Asselah. HCV Polypeptide Sequence
7 The HCV Polymerase (NS5B) The active site of the HCV polymerase is highly conserved Explains why sofosbuvir is the backbone of several regimens
8 What s Special About the Active Site of the HCV Polymerase? Feature Therapeutic Implication Highly conserved across genotypes Pangenotypic efficacy of potent inhibitors Low replicative fitness conferred by amino acid substitutions High resistance barrier
9 Where HCV Therapy Stands Now Interferon is gone in the U.S.; ribavirin not quite SVR in over 95% of patients Difficult to treat populations no longer difficult African-Americans HIV coinfected Cirrhosis Older age Renal failure and transplant Liver transplant Persons who use IV drugs (PWID) Confidence that SVR12 = cure Cost and access issues persist, but improving
10 Rising Cure Rates for Chronic HCV (GT1) 100% 80% Telaprevir or Boceprevir + PegIFN/RBV PR/SMV PR/SOF 80-90% IFN-Free DAA Combination Regimens >95% Cure Rate* 60% 40% IFN/RBV PegIFN/RBV 44% 70-80% 35% 20% IFN 16% 0% Year
11 The Evolution of HCV Therapy Ledipasvir + sofosbuvir (GT1) Telaprevir and boceprevir Daclatasvir: DCV+ASV (Japan) DCV+SOF (Europe) Simeprevir + sofosbuvir (GT1) Paritaprevir/rombitasvir/ dasabuvir ± RBV (GT1) DCV + SOF (GT3) (GT1 2016) Sofosbuvir + velpatasvir (all genotypes) Glecaprevir + Pibrentasvir (all genotypes) Interferon Era Curability of HCV without IFN Simeprevir, sofosbuvir with IFN (GT1) First approved IFN-free therapy: sofosbuvir + RBV (GT2,3) DAA: direct-acting antiviral; GT: genotype; IFN: interferon; PI: protease inhibitor; NI: nucleoside/nucleotide inhibitor; RBV: ribavirin; r: ritonavir. Grazoprevir+ Elbasvir (GT1,4) Sofosbuvir + Velpatasvir+ Voxilaprevir (all genotypes)
12 Approved Direct-Acting Antiviral Agents from Multiple Classes: Combination Regimens for HCV in 2017 Structural domain Nonstructural domain P 7 5 UTR Core E1 E2 NS2 NS4B NS3 NS5A NS5B 4A 3 UTR Protease Polymerase Ribavirin (RBV) NS3 Protease Inhibitors Simeprevir (SMV) Paritaprevir/ritonavir (PTV/r) Grazoprevir (GZR) Glecaprevir (GLE) Voxilaprevir (VOX) NS5A Replication Complex Inhibitors Daclatasvir (DCV) Ledipasvir (LDV) Ombitasvir (OMV) Elbasvir (EBV) Velpatasvir (VEL) Pibrentasvir (PIB) NS5B NUC Inhibitors Sofosbuvir (SOF) NS5B Non-NUC Inhibitors (NNI) Dasabuvir (DSV) previr = protease inhibitor; asvir = NS5A inhibitor; uvir = polymerase inhibitor Courtesy of Albert Min MD.
13 SVR and All-Cause Mortality in CHC Patients with Advanced Fibrosis 530 patients with all genotypes followed for a median of 8.4 years 10-Year Cumulative Occurrence Rate (%) SVR patients Non-SVR patients Baseline factors significantly associated with all-cause mortality: Older age Genotype 3 (2-fold increase in mortality and HCC) Higher Ishak fibrosis score Diabetes Severe alcohol use 0 All-Cause Mortality Liver-Related Mortality or Liver Transplant HCC Liver Failure Van der Meer A, et al. JAMA. 2012; 308:
14 Cirrhosis Regression and Fibrosis Reduction Following SVR (any genotype) Cirrhosis Regression in 61% of Patients 100% 80% 15 Sample Liver Biopsy Pre-treatment (F4) Post-treatment (F3) 60% 40% % 0% Pre-treatment Post-treatment 7 2 F1 F2 F3 F4 Fibrosis Reduction After treatment, the area of fibrosis decreased in 34/38 (89%) of patients Post-treatment liver biopsies showed a significantly reduced area of fibrosis, with a median individual decrease of 71.8% Prospective study of patients with pre-treatment cirrhosis and an SVR with IFN-based therapy (enrolled in ) to assess the impact of SVR on the full spectrum of histopathologic features of HCV-related cirrhosis. N=38, median f/u 67 months (range, months). Adapted from D Ambrosio R, et al. Hepatology. 2012;56:
15 Evolution of Portal Pressure After DAA Therapy HVPG (mmhg) HVPG Absolute : ± 0.38 mmhg; p<0.001 Relative : -23 ± 2.9% Subclinical portal hypertension at BL HVPG mmhg at BL Pronounced portal hypertension at BL Resolved 63% No progression Resolved 14% Regression 29% No progression No resolution Regression 5% Increase 20% 0 BL BL FU FU 13.1 ± 0.7 mmhg 10.4 ± 0.79 mmhg Earlier portal hypertension is more reversible than advanced PHT Mandorfer M, et al. EASL Barcelona. #PS005.
16 Benefits of SVR Decreased liver mortality Decreased all-cause mortality Regression of fibrosis Improvement in portal pressures
17 Extra-hepatic Manifestations of HCV Infection Neuropsychiatric manifestations Thyroid dysfunction Mixed cryoglobulinemia Hematological disorders/ malignancies Type II diabetes Cardiovascular/ metabolic diseases Renal impairment Peripheral neuropathy Cacoub P, et al. Dig Liver Dis 2014; 46(Suppl 5):S165 S173; Negro F, et al. Gastroenterology 2015; 149: ; Englert Y, et al. Fertil Steril 2007; 88:607 11; Samuel DG & Rees IW. Frontline Gastroenterol2013; 4:
18 Treatment of HCV Is Associated with Reduced Risk for Type 2 Diabetes Mellitus Cumulative development rate of T2DM Japanese retrospective study: 2842 patients treated with IFN ± RBV were followed for a mean of 6.4 years p< Follow up (years) Non-SVR (n = 1667) SVR (n = 1175) SVR was associated with a 66% reduction in the development of T2DM Patients without IFG and/or T2DM Spanish HCV chronic HCV cohort study: 1059 patients treated with IFN + RBV for 24/48 weeks SVR Censored NR Censored P= Follow-up (months) SVR reduces the risk of IFG and/or T2DM development 1.. Arase Y, et al. Hepatology 2009; 49: ; 2. Romero-Gomez M, et al. J Hepatol 2008; 47:
19 Cumulative incidence (%) Treatment of HCV Is Associated with Reduced Risk for Cardiovascular Complications Large Taiwanese chronic HCV cohort study: 12,384 patients treated with pegifn/rbv and 24,768 untreated matched controls were followed up for a mean of 3.3 years and 3.2 years, respectively Untreated cohort Treated cohort Ischemic stroke, p= Follow-up (years) Antiviral treatment was associated with a 38% lower risk for ischemic stroke Cumulative incidence (%) Antiviral treatment was associated with a 23% lower risk for ACS ACS, acute coronary syndrome. Hsu YC, et al. Gut 2015; 64: Untreated cohort Treated cohort Acute coronary syndrome, p= Follow-up (years)
20 Treatment of HCV Is Associated with Reduced Risk for End Stage Renal Disease Large Taiwanese prospective chronic HCV cohort study: 12,384 patients treated with pegifn/rbv and 24,768 untreated matched controls were followed up for a mean of 3.3 years and 3.2 years, respectively Cumulative incidence (%) Untreated cohort Treated cohort End-stage renal disease, p<0.001 Hsu YC, et al. Gut 2015; 64: ; Follow-up (years)
21 Benefits of SVR Reduced risk of the development of type 2 DM Reduced risk of cardiovascular complications Reduced risk of development of renal disease
22 Classes of Medications Used for HCV Treatment NS3-4A Protease Inhibitors ( Previr ) NS5A Inhibitors ( Asvir ) NS5B Inhibitors: ( Buvir ) Other Nucleoside Analogues Non-Nucleoside Analogues Grazoprevir Daclatasvir Sofosbuvir Dasabuvir Ribavirin Paritaprevir Elbasvir Simeprevir Glecaprevir Voxilaprevir Ledipasvir Ombitasvir Velpatasvir Combination Therapies Trade Name Glecaprevir / Pibrentasvir Mavyret Grazeprevir/Elbasvir Zepatier Paritaprevir/Ombitasvir/Dasabuvir Viekira XR Sofosbuvir/Ledipasvir Harvoni Sofosbuvir/Velpatasvir Epclusa Sofosbuvir/Velpatasvir/Voxilaprevir Vosevi
23 Genotype 1 Regimens Updated September
24 Recommended and Alternative Regimens for GT1 Without Cirrhosis No Distinction Between Naïve & IFN-Experienced Recommended Alternative Nucleotide No nucleotide GLE/PIB LDV/SOF SOF + VEL DCV + SOF SMV + SOF GZR/EB R OBV/PTV/RT V + DSV GT1a 8 wks (8 wks if HCV RNA<6M IU/ml, non- AA, no HIV) 12 wks 16 wks + RBV + RBV GT1b 8 wks (8 wks if HCV RNA<6M IU/ml, non- AA, no HIV) 12 wks If NS5A RAVs present (GT1a only) Accessed 9/17
25 Recommended and Alternative Regimens for GT1a with Compensated Cirrhosis Recommended Alternative Nucleotide No nucleotide GLE/PI B LDV/SO F SOF + VEL DCV + SOF SMV + SOF GZR/EBR OBV/PTV/RT V + DSV GT1a - Naive - PR exp + RBV or 24 wks w/o RBV 24 wks ± RBV 24 wks ± RBV 24 wks ± RBV* 24 wks ± RBV* 16 wks + RBV 16 wks + RBV 24 wks + RBV 24 wks + RBV *Not w/q80k If NS5A RAVs present. Accessed 9/17
26 Recommended and Alternative Regimens for GT1b with Compensated Cirrhosis Recommended Alternative Nucleotide No nucleotide GLE/PI B LDV/SO F SOF + VEL DCV + SOF SMV + SOF GZR/EBR OBV/PTV/RT V + DSV GT1b - Naive 24 wks ± RBV 24 wks ± RBV* - PR exp + RBV or 24 wks 24 wks ± RBV 24 wks ± RBV* *Not w/q80k If NS5A RAVs present. Accessed 9/17
27 Treatment of DAA Failures: The 2017 Regimens Approved in the US
28 Treatment of Genotype 1 DAA Failures Genotype Previous Regimen Treatment Duration GLE/PIB 1a, 1b NS5a without prior treatment with an NS3/4A PI GLE/PIB 1a, 1b NS3/4A PI without prior treatment with an NS5A 16 weeks 12 weeks SOF/VEL/VOX 1a,1b NS5A inhibitor 12 weeks SOF/VEL/VOX 1a Sofosbuvir without an NS5A inhibitor 12 weeks Accessed 9/17
29 Genotype 2
30 Recommended Regimens for GT2, Naive without and with Compensated Cirrhosis GLE/PI B SOF + VEL DCV + SOF Noncirrhotic 8 wks Cirrhotic *Not w/q80k If NS5A RAVs present. Accessed 9/17
31 Recommended Regimens for GT2, Treatment Experienced without and with Compensated Cirrhosis Previous Regimen Treatment Duration (No cirrhosis) Treatment Duration (cirrhosis) GLE/PIB PEG/RBV +/- SOF 8 weeks 12 weeks SOF/VEL/VOX NS5A inhibitor 12 weeks 12 weeks SOF/VEL/VOX Sofosbuvir without an NS5A inhibitor 12 weeks 12 weeks Accessed 9/17
32 Genotype 3
33 Recommended Regimens for GT3, Naive without and with Compensated Cirrhosis GLE/PI B SOF + VEL DCV + SOF Noncirrhotic 8 wks Cirrhotic 24 wks *Not w/q80k If NS5A RAVs present. Accessed 9/17
34 Recommended Regimens for GT3, Treatment Experienced without and with Compensated Cirrhosis Previous Regimen Treatment Duration (No cirrhosis) Treatment Duration (cirrhosis) GLE/PIB PEG/RBV +/- SOF 16 weeks 16 weeks SOF/VEL/VOX NS5A inhibitor 12 weeks 12 weeks SOF/VEL/VOX Sofosbuvir without an NS5A inhibitor DAC/SOF PEG/RBV 12 weeks 12 weeks 12 weeks DAC/SOF/RBV PEG/RBV 24 weeks Accessed 9/17
35 Decompensated Cirrhosis
36 SOLAR-1: LDV/SOF + RBV in Decompensated Cirrhotics: Genotypes 1 and 4, Childs-Pugh B and C LDV/SOF + RBV 12 Weeks LDV/SOF + RBV 24 Weeks SVR12 (%) /52 42/47 Overall 26/30 24/27 19/22 18/20 CPT B CPT C Charlton M, et al. Gastroenterology. 2015;149:
37 ASTRAL-4: SOF/VEL FDC for Treatment of HCV in Patients with Decompensated Liver Disease SVR24 rates (%) / 90 82/ 87 79/ 90 60/ 68 65/ 68 Safety d/c due to AE 3%; death 3% (9) AE more frequent with RBV Fatigue (29%); nausea (23%); HA (22%); anemia (13%; 31% in RBV arm) 67/ 71 7/ 14 11/ 13 6/ 12 G2: 4/4 G4: 4/4 G2: 4/4 G4: 2/2 Overall G1 G3 G2, 4, 6 BT Relapse LTFU Death G2: 4/4 G4: 2/2 G6: 1/ Charlton MR, et al. AASLD San Francisco. #LB-13; O Leary J, et al. EASL Barcelona. #SAT-169. RBV dose: Hb <10 = 23%; Hb <8.5 = 7% RBV decreased in 37% and d/c in 17% Bili <3 x ULN
38 What Therapy Should Be Used for Decompensated Cirrhotics? 1. Only regimens containing an NS5A inhibitor and polymerase inhibitor should be used for decompensated cirrhotic patients 2. Protease inhibitors should not be used in decompensated cirrhotics because they accumulate to potentially toxic levels 3. Decompensated cirrhotics can be safely treated at a transplant center or in close coordination with a transplant center 4. Decompensated cirrhotics should not be treated in the primary care setting hcvguidelines.org. Feb 24; EASL Recommendations. J Hepatol
39 Renal Failure
40 Treatment of patients with renal impairment No dose adjustment is required in patients with mild, moderate or severe renal impairment, including dialysis with the following regimens: GLE/PIB GRZ/ELB SVR rates similar to non-renal failure patients Sofosbuvir containing regimens should not be used in patients with a GFR < 30 Mavyret PI 2017 Zepatier PI 2016,
41 Paradigm of HCV Therapy for Renal Failure Patients Past: Difficult to use interferon + ribavirin in renal failure Renal transplantation historically withheld for HCV+ patients with hepatic fibrosis ( we won t transplant till HCV cured ) Concern about progression of fibrosis post-transplant Present Effective and safe DAA therapy available for renal failure patients Non-renal transplant candidates should be offered treatment If wait list is much shorter for an HCV+ kidney, may be better to proceed with transplant and treat the HCV after transplant Future Transplant HCV- patients with HCV+ kidneys? Being studied
42 HCV Therapy: Almost at the Summit But Still Climbing The Quest: Pangenotypic regimens that cover resistant variants associated with first generation NS5A and protease inhibitors
43 Second Generation Combination Pangenotypic Regimens Protease Inhibitor NS5A Inhibitor Nucleotide Polymerase Inhibitor FDA Status Glecaprevir Pibrentasvir Approved GS-9857 Velpatasvir Sofosbuvir Approved Grazoprevir Ruzasvir Uprifosbuvir Under study
44 SUMMARY OF GLE/PIB STUDIES STUDY Genotype C/NC TN/TE Duration (wks) SVR Endurance-1 1 NC TN/TE 8 99% Surveyor-2 2 NC TN/TE 8 98% 4 NC TN/TE 8 93% 5 NC TN/TE 8 100% 5 NC TN/TE % 6 NC TN/TE 8 100% 6 NC TN/TE % Expedition 1 1,2,4,5,6 C TN/TE % Endurance 3 3 NC TN 8, 12 95%, 95% Surveyor 2 Pt 3 3 C/NC TN/TE 12, 16 98%, 96% Magellan 1 1 C/NC TE PI 12, NS5A 16 92%, 94% C-cirrhosis, NC-non-cirrhosis, TN- treatment-naïve, TE-treatment experienced Mavyret PI 2017
45 SUMMARY OF SOF/VEL/VOX STUDIES: All treatments 12 weeks STUDY Genotype NC/C TN/TE SVR Polaris 1 1 NC/C TE with NS5A 97% 2 NC/C TE with NS5A 100% 3 NC/C TE with NS5A 95% 4 NC/C TE with NS5A 91% 5 NC/C TE with NS5A 100% 6 NC/C TE with NS5A 100% Polaris 4 1 NC/C TE without prior NS5A 96% 2 NC/C TE without prior NS5A 100% 3 NC/C TE without prior NS5A 96% C-cirrhosis, NC-non-cirrhosis, TN- treatment-naïve, TE-treatment experienced Vosevi PI 2017
46 Summary We are now in an era of highly effective interferon free treatment Historically difficult to treat patients are no longer considered difficult to treat HIV coinfected patients have similar efficacy, must be mindful of drug-drug interactions PWID should be treated with appropriate avaliable expertise in addiction medicine w/harm reduction There is significant fibrosis regression, reduction in liver complications, and all-cause mortality post-svr There is no justification for withholding treatment from HCV infected patients regardless of degree of fibrosis Post-SVR patients with advanced fibrosis or cirrhosis must be monitored for liver cancer
47 On Line Treatment Guideline Links NYS DOH AASLD/IDSA
Current HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationCurrent HCV Treatment by Genotype Empire Liver Foundation Ira M. Jacobson, MD
Current HCV Treatment by Genotype Empire Liver Foundation Ira M. Jacobson, MD Chairman, Department of Medicine Mount Sinai Beth Israel Professor of Medicine Co-Director, Liver Institute Icahn School of
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationTreatment of HCV : 100 % cure?
Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationNew Hepatitis C Antivirals
New Hepatitis C Antivirals Kris Stewart, BSP, MD, FRCPC Drug Therapy Conference College of Medicine, University of Saskatchewan September 23, 2016 Disclosures I have received research and program support
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationTerapie attuali. Eradicazione di HCV e nuove prospettive:
Eradicazione di HCV e nuove prospettive: Terapie attuali Luisa Pasulo U.S.C. Gastroenterologia Epatologia e Trapiantologia Ospedale Papa Giovanni XXIII - Bergamo From Infection to liver disease Infezione
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationProgram Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through
More informationHCV Screening, Management and Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management and Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More information*If RASs at baseline Harvoni x 12 wks 95% (83/87; ION-2) Zepatier + RBV x 12 wks Mavyret x 12 wks 92% (23/25; MAGELLAN-1)
PATIENTS WITHOUT CIRRHOSIS GENOTYPE Naïve Harvoni x 8 wks (if HCV 97% (119/123; ION-3), 97% - HCV- Epclusa x 12 wks 98% (206/210; ASTRAL-1), RNA
More informationHepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More information